The United States Food and Drug Administration (FDA) recently announced that it had approved Profound Medical’s Sonalleve MR-guided High Intensity Focused Ultrasound (MR-HIFU) system for the treatment of osteoid osteoma (OO) in the extremities. This marks the first focused ultrasound regulatory approval that will directly impact pediatric patients, and it is the sixth indication to earn approval in the US.
Researchers in Toronto are investigating the safety of a second focused ultrasound treatment. Essential tremor patients who were treated successfully on one side will receive a second procedure on the other.
Foundation Council member Harry Lester shares his Stage IV lung cancer diagnosis, his experience with immunotherapy, and his hope for focused ultrasound to increase the effectiveness of cancer treatments.
Beginning in April 2021, the National Health Service (NHS) England – the country’s publicly funded healthcare system – has commissioned focused ultrasound as a clinical service to treat essential tremor.
Elisa Konofagou, PhD, and her research team at Columbia University recently treated the first patient in their clinical trial to open the blood-brain barrier in patients with Alzheimer’s disease using a novel, neuronavigation-guided focused ultrasound system.
CarThera was awarded a €2 million grant from the European Innovation Council Accelerator Pilot to finish developing its SonoCloud-9 device for treating glioblastoma patients. A multicenter pilot clinical study for the device is underway.